Journey Medical reports Q1 net loss narrows to $4.1M; Emrosi launch underway

Journey Medical Corp

2025-Q1 EPS reported -$0.18 revenue$13,139,000

Net loss $4.1M ($0.18/sh) vs $10.4M loss ($0.53/sh) in Q1 2024.
Revenue $13.1M, flat YoY; includes $2.1M from Emrosi launch.
Gross margin improved to 64% from 54% YoY; R&D costs nil vs $7.9M.
Cash $21.1M at March 31, 2025 (vs $20.3M at Dec 31, 2024).
Emrosi commercial launch started April 7; Phase 3 results published in JAMA Dermatology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.